Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma

Autor:	Gwynn D. Long, Keith M. Sullivan, David A. Rizzieri, Bercedis Peterson, Constance Cirrincione, Nelson J. Chao, Wendi A. Bacon, Mitchell E. Horwitz, Kelly Corbet, Li-Wen Huang, Sascha A. Tuchman, Cristina Gasparetto
Jazyk:	angličtina
Rok vydání:	2017
Předmět:	Male Oncology Cancer Research medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment Transplantation Autologous Article 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Maintenance therapy Internal medicine medicine Humans Multiple myeloma Retrospective Studies Chemotherapy business.industry Hazard ratio Age Factors Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged medicine.disease Confidence interval Surgery Survival Rate Transplantation 030220 oncology & carcinogenesis Toxicity Female Multiple Myeloma business 030215 immunology
ISSN:	1099-1069
Popis:	We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% confidence interval [CI] 0.86–1.03); since the CI upper bound was 1.05. Toxicity was similar across ages and transplant-related mortality was minimal. 28% of subjects
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f734d0a023d67c6297b8b21e1d0ac236 http://oro.open.ac.uk/78350/1/https_www.ncbi.nlm.nih.gov_pmc_articles_PMC5949235_pdf_nihms963449.pdf Zobrazit plný text záznamu Plný text